Recro Enters Development Agreement With Astex Pharmaceuticals
Recro Pharma (NASDAQ: REPH) announced a new development agreement with Astex Pharmaceuticals, a leader in cancer therapeutics. This partnership reinforces Recro's commitment to building strong relationships with CDMO customers. Recro specializes in complex formulation and manufacturing for oral solid dose products, offering services from early feasibility to commercial manufacturing. Their facilities span 120,000 square feet in Gainesville, Georgia, supporting a wide range of pharmaceutical development needs.
- New development agreement signed with Astex Pharmaceuticals, enhancing CDMO customer base.
- Recro's expertise in complex formulation and manufacturing increases their market position.
- None.
EXTON, Pa., May 18, 2021 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (“Recro”; NASD: REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufacturing challenges for companies developing oral solid dose drug products, today announced the signing of a new development agreement with Astex Pharmaceuticals, Inc.
“We are excited to add Astex, a leading developer of novel therapeutics for cancer, to our growing list of CDMO customers,” said Bill Hirschman, vice president of sales and marketing for Recro. “The support we have been engaged to provide represents the type of durable, trusted relationship we work every day to build with our customers. We look forward to an ever expanding partnership and wish Astex continued success.”
About Recro
Recro (NASD: REPH) is a contract development and manufacturing organization (CDMO) with capabilities from early feasibility to commercial manufacturing. With an expertise in solving complex manufacturing problems, Recro is a CDMO providing oral solid dosage form development, end-to-end regulatory support, clinical and commercial manufacturing, and packaging and logistics services to the global pharmaceutical market.
In addition to our experience in handling DEA controlled substances and developing and manufacturing modified release oral solid dosage forms, Recro has the expertise to deliver on our clients’ pharmaceutical development and manufacturing projects, regardless of complexity level. We do all of this in our best-in-class facilities, which total 120,000 square feet, in Gainesville, Georgia.
For more information about Recro’s CDMO solutions, visit recrocdmo.com.
Cautionary Statement Regarding Forward Looking Statements
This press release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These statements, among other things, relate to the Company’s ability to manage costs and to achieve its financial goals; to operate under increased leverage and associated lending covenants; to pay its debt under its credit agreement and to maintain relationships with CDMO commercial partners and develop additional commercial partnerships. The words "anticipate", "believe", "could", "estimate", “upcoming”, "expect", "intend", "may", "plan", "predict", "project", "will" and similar terms and phrases may be used to identify forward-looking statements in this press release. Our operations involve risks and uncertainties, many of which are outside our control, and any one of which, or a combination of which, could materially affect our results of operations and whether the forward-looking statements ultimately prove to be correct. Factors that could cause the Company’s actual outcomes to differ materially from those expressed in or underlying these forward-looking statements include the ongoing economic and social consequences of the COVID-19 pandemic, including any adverse impact on the customer ordering patterns or inventory rebalancing or disruption in raw materials or supply chain; demand for the Company’s services, which depends in part on customers’ research and development and the clinical plans and market success of their products; customers' changing inventory requirements and manufacturing plans; customers and prospective customers decisions to move forward with the Company’s manufacturing services; the average profitability, or mix, of the products the Company manufactures; the Company’s ability to enhance existing or introduce new services in a timely manner; fluctuations in the costs, availability, and suitability of the components of the products the Company manufactures, including active pharmaceutical ingredients, excipients, purchased components and raw materials, or the Company’s customers facing increasing or new competition. These forward-looking statements should be considered together with the risks and uncertainties that may affect our business and future results presented herein along with those risks and uncertainties discussed in our filings with the Securities and Exchange Commission at www.sec.gov. These forward-looking statements are based on information currently available to us, and we assume no obligation to update any forward-looking statements except as required by applicable law.
| Contacts: | ||
| Stephanie Diaz (Investors) Vida Strategic Partners 415-675-7401 sdiaz@vidasp.com | Tim Brons (Media) Vida Strategic Partners 415-675-7402 tbrons@vidasp.com | Ryan D. Lake (CFO) Recro (484) 395-2436 ryan.lake@recroCDMO.com |
FAQ
What is the recent development agreement Recro Pharma signed?
How does Recro Pharma support its customers?
What is the stock symbol for Recro Pharma?
Where are Recro Pharma's facilities located?
